Original language | English (US) |
---|---|
Pages (from-to) | 1171-1175 |
Number of pages | 5 |
Journal | Leukemia |
Volume | 36 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2022 |
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Leukemia, Vol. 36, No. 4, 04.2022, p. 1171-1175.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
AU - Sharman, Jeff P.
AU - Egyed, Miklos
AU - Jurczak, Wojciech
AU - Skarbnik, Alan
AU - Pagel, John M.
AU - Flinn, Ian W.
AU - Kamdar, Manali
AU - Munir, Talha
AU - Walewska, Renata
AU - Corbett, Gillian
AU - Fogliatto, Laura Maria
AU - Herishanu, Yair
AU - Banerji, Versha
AU - Coutre, Steven
AU - Follows, George
AU - Walker, Patricia
AU - Karlsson, Karin
AU - Ghia, Paolo
AU - Janssens, Ann
AU - Cymbalista, Florence
AU - Woyach, Jennifer A.
AU - Ferrant, Emmanuelle
AU - Wierda, William G.
AU - Munugalavadla, Veerendra
AU - Yu, Ting
AU - Wang, Min Hui
AU - Byrd, John C.
N1 - Funding Information: JS: Research funding from Seattle Genetics; research funding and consulting from AbbVie, AstraZeneca, BeiGene, BMS, Genentech, Gilead, Lilly, Pharmacyclics, TG Therapeutics; scientific board for Centessa; employment from US Oncology. ME: Nothing to disclose. WJ: Research funding from AstraZeneca, Janssen, and Loxo. AS: Consulting fees from AbbVie, AstraZeneca, Celgene, Genentech, GenMab, Kite, MorphoSys, Novartis, Pharmacyclics, Janssen, Alexion, Seattle Genetics, and TG Therapeutics; honoraria from AbbVie, AstraZeneca, BeiGene, Celgene, Genentech, Jazz Pharmaceuticals, Kite, Seattle Genetics, Pharmacyclics, Janssen, and TG Therapeutics; data safety monitoring board/advisory board participation for Alexion. JP: Consulting and speaker bureau for AstraZeneca. IF: Consulting fees from AbbVie, AstraZeneca, BeiGene, Genentech, Gilead, Great Point Partners, Iksuda, Janssen, Juno, Kite, MorphoSys, Nurix, Pharmacyclics, Roche, Seattle Genetics, Takeda, TG Therapeutics, Unum, Verastem, and Yingli; grants from AbbVie, Acerta, Agios, ArQule, AstraZeneca, BeiGene, Calithera, Celgene, Constellation, Curis, Forma, Forty Seven, Genentech, Gilead, IGM Biosciences, Incyte, Infinity, Janssen, Juno, Karyopharm, Kite, Loxo, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, Portola, Rhizen, Roche, Seattle Genetics, Takeda, Teva, TG Therapeutics, Trilium, Triphase, Unum, and Verastem. MK: Research support/funding from TG Therapeutics and Genentech; consulting for AbbVie, Karyopharm, Kite, AstraZeneca, Celgene/Bristol Myers Squibb, Adaptive, and ADC Therapeutics; speaker’s bureau for Seagen; data monitoring committee member for Celgene and Genentech. TM: Consulting/advisory role for Morphosys, Sunesis, AstraZeneca, Janssen; honoraria from Janssen, AstraZeneca, Gilead, and Novartis. RW: Nothing to disclose. GC: Nothing to disclose. LMF: Nothing to disclose. YH: Honoraria from AbbVie, Janssen, AstraZeneca, and Roche. VB: Honoraria from AbbVie, Janssen, and AstraZeneca; grant funding from the Canadian Institutes of Health Research, Leukemia Lymphoma Society of Canada, CancerCare Manitoba Foundation, and the Hairy Cell Leukemia Foundation. SC: Honoraria from Janssen Oncology and Pharmacyclics; consulting for AbbVie, Adaptive Biotechnologies, AstraZeneca, BeiGene, Genentech/Roche, Janssen Oncology, and Pharmacyclics; clinical research support from AbbVie, Acerta Pharma/AstraZeneca, Janssen Oncology, Pharmacyclics; expert testimony for Genentech. GF: Consulting fees from AstraZeneca, Roche, AbbVie, Janssen, Karyopharm, Bristol Myers Squibb, and Centessa; honoraria from AstraZeneca, Roche, AbbVie, and Janssen; travel support from Roche, Janssen, and Bristol Myers Squibb. PW: Travel support from Roche; honoraria from AstraZeneca. KK: Nothing to disclose. PG: Honoraria from AbbVie, AstraZeneca, ArQule/MSD, BeiGene, Janssen, Loxo/Lilly, and Roche; research support from AbbVie, AstraZeneca, Janssen, and Sunesis. AJ: Consulting fees from Janssen, Roche, Gilead, AbbVie, Novartis, Amgen, Sanofi-Genzyme, and AstraZeneca; honoraria from Janssen, Roche, AbbVie, Novartis, Amgen, AstraZeneca, and BeiGene; travel support from AbbVie, Roche, Amgen, and Bristol Myers Squibb/Celgene. FC: Consulting fees from AbbVie; honoraria from Roche, AbbVie, AstraZeneca, and Janssen; travel support from AstraZeneca, Roche, and AbbVie. JW: Consulting for AbbVie, Janssen, Pharmacyclics, BeiGene, AstraZeneca, ArQule, and Loxo; research support from Loxo and AbbVie; clinical trial support from Karyopharm, Morphosys, Pharmacyclics, and Janssen. EF: Honoraria from Janssen-Cilag; payment for expert testimony from Gilead, AbbVie, and Janssen-Cilag. WW: Grants/ contracts from GSK/Novartis, AbbVie, Genentech, Pharmacyclics, AstraZeneca/Acerta, Gilead, Juno, Kite, Sunesis, Miragen, Oncternal, Cyclacel, Loxo, Janssen, and Xencor. VM: Stock from and employment by AstraZeneca; family member association with Gilead. TY: Employment by AstraZeneca; stock from AstraZeneca, Johnson & Johnson, and AbbVie. MHW: Stock from and employment by AstraZeneca. JB: Stock and other ownership interests from Vincerx; honoraria from Pharmacyclics, AstraZeneca, Novartis, Syndax, and Trillium; consulting or advisory role for Acerta, Janssen, Kura, Novartis, Syndax, and AstraZeneca; research funding from Acerta, Pharmacyclics, and Zencor; patents, royalties, and other intellectual property from OSU Patents; travel support from Gilead, Janssen, Novartis, Pharmacyclics, and TG Therapeutics. Funding Information: The authors are grateful for the contributions of our co-author, colleague, and friend Dr. Steven Coutre, who sadly passed away just before publication of this report; he will be dearly missed. The study was funded by Acerta Pharma, South San Francisco, CA, a member of the AstraZeneca Group. Medical writing assistance, funded by AstraZeneca, was provided by Tracy Diaz, PhD, and Cindy Gobbel, PhD, of Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ.
PY - 2022/4
Y1 - 2022/4
UR - http://www.scopus.com/inward/record.url?scp=85122061347&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122061347&partnerID=8YFLogxK
U2 - 10.1038/s41375-021-01485-x
DO - 10.1038/s41375-021-01485-x
M3 - Article
C2 - 34974526
AN - SCOPUS:85122061347
SN - 0887-6924
VL - 36
SP - 1171
EP - 1175
JO - Leukemia
JF - Leukemia
IS - 4
ER -